

SAFETY DATA SHEETS

This SDS packet was issued with item:

078929352

The safety data sheets (SDS) in this packet apply to one or more components included in the items listed below. Items listed below may require one or more SDS. Please refer to invoice for specific item number(s).

078038603 078038611

SAFETY DATA SHEET



1. Identification

Product identifier	Fluvac Innovator 4
Other means of identification	
Synonyms	Fluvac Innovator® 4 * FLUVAC® INNOVATOR 4 * Fluvac Innovator EWT * Encephalomyelitis-Influenza Vaccine, Eastern & Western, Killed Virus, Tetanus Toxoid
Recommended use	Veterinary vaccine
Recommended restrictions	Not for human use
Manufacturer/Importer/Supplier/Distributor information	
Company Name (US)	Zoetis Inc. 10 Sylvan Way Parsippany, New Jersey 07054 (USA)
Rocky Mountain Poison and Drug Center	1-866-531-8896
Product Support/Technical Services	1-800-366-5288
Emergency telephone numbers	CHEMTREC (24 hours): 1-800-424-9300 International CHEMTREC (24 hours): +1-703-527-3887
Company Name (EU)	Zoetis Belgium S.A. Mercuriusstraat 20 1930 Zaventem Belgium
Emergency telephone number	International CHEMTREC (24 hours): +1-703-527-3887
Contact E-Mail	VMIPSrecords@zoetis.com

2. Hazard(s) identification

Physical hazards	Not classified.
Health hazards	Not classified.
Environmental hazards	Not classified.
OSHA defined hazards	Not classified.
Label elements	
Hazard symbol	None.
Signal word	None.
Hazard statement	The mixture does not meet the criteria for classification.
Precautionary statement	
Prevention	Observe good industrial hygiene practices.
Response	Wash hands after handling.
Storage	Store away from incompatible materials.
Disposal	Dispose of waste and residues in accordance with local authority requirements.
Hazard(s) not otherwise classified (HNOC)	None known.
Supplemental information	Direct contact with eyes may cause temporary irritation. In the event of accidental injection, an allergic reaction may occur. This product is an oil-adjuvanted suspension. Oil-adjuvant containing products may cause severe vasospasm following accidental injection.

3. Composition/information on ingredients

Mixtures

Chemical name	Common name and synonyms	CAS number	%
Squalene		111-02-4	<10
Clostridium tetani toxoid		Not assigned	*
EASTERN EQUINE ENCEPHALOMYELITIS		Not Assigned	*
Equine Influenza Virus, Kentucky 97 (EIV)		Not Assigned	*
Neomycin B		119-04-0	##
Polymyxin B		1404-26-8	##
Thimerosal		54-64-8	##
WESTERN EQUINE ENCEPHALOMYELITIS		Not Assigned	*

Composition comments

Trace

* Non-hazardous Ingredients

In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

4. First-aid measures

Inhalation

Move to fresh air. Call a physician if symptoms develop or persist.

Skin contact

In the case of skin contact, immediately wash the skin with plenty of soap and water. In the event of accidental self injection or needle stick injury, wash the injury thoroughly with clean running water. Get medical attention immediately.

Eye contact

Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician. Remove contact lenses, if present and easy to do.

Ingestion

Rinse mouth. Call a physician or poison control center immediately. Only induce vomiting at the instruction of medical personnel. Never give anything by mouth to an unconscious person.

Most important symptoms/effects, acute and delayed

Direct contact with eyes may cause temporary irritation. Exposure may cause temporary irritation, redness, or discomfort. In the event of accidental injection, an allergic reaction may occur. Signs and symptoms might include skin rash, itching, redness or swelling. Respiratory reactions may be characterized by rhinitis, sneezing, scratchy throat, oral mucosal edema, laryngeal mucosal edema, coughing, shortness of breath, wheezing, and chest pain. Asthma like reactions occur with acute exposures in sensitized patients. This product is an oil-adjuvanted suspension. Oil-adjuvant containing products may cause severe vasospasm following accidental injection.

Indication of immediate medical attention and special treatment needed

Treat symptomatically. Where parenteral oil-adjuvanted vaccine exposure has occurred, the patient should be promptly evaluated for the development of vasospasm and/or compartment syndrome.

General information

For personal protection, see section 8 of the SDS. Ensure that medical personnel are aware of the material(s) involved, and take precautions to protect themselves.

5. Fire-fighting measures

Suitable extinguishing media

Water fog. Foam. Dry chemical powder. Carbon dioxide (CO2).

Unsuitable extinguishing media

Do not use water jet as an extinguisher, as this will spread the fire.

Specific hazards arising from the chemical

During fire, gases hazardous to health may be formed.

Special protective equipment and precautions for firefighters

Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Fire fighting equipment/instructions

Move containers from fire area if you can do so without risk.

Specific methods

Use standard firefighting procedures and consider the hazards of other involved materials.

General fire hazards

No unusual fire or explosion hazards noted.

6. Accidental release measures

Personal precautions, protective equipment and emergency procedures

Keep unnecessary personnel away. For personal protection, see section 8 of the SDS.

Methods and materials for containment and cleaning up

Large Spills: Stop the flow of material, if this is without risk. Cover with plastic sheet to prevent spreading. Absorb in vermiculite, dry sand or earth and place into containers. Following product recovery, flush area with water.

Small Spills: Wipe up with absorbent material (e.g. cloth, fleece). Clean surface thoroughly to remove residual contamination.

Never return spills to original containers for re-use. For waste disposal, see section 13 of the SDS. Avoid discharge into drains, water courses or onto the ground.

Environmental precautions**7. Handling and storage****Precautions for safe handling**

Avoid contact with eyes, skin, and clothing. Avoid breathing mist or vapor. Avoid accidental injection. Wash thoroughly after handling. When using, do not eat, drink or smoke. Wear personal protective equipment. Avoid release to the environment. Observe good industrial hygiene practices.

Conditions for safe storage, including any incompatibilities

Store out of direct sunlight in dark, dry conditions. @ 2 - 7°C (36 - 45°F). Do not freeze. Store in original tightly closed container. Keep away from heat, sparks and open flame. Store away from incompatible materials (see Section 10 of the SDS).

8. Exposure controls/personal protection**Occupational exposure limits**

The following constituents are the only constituents of the product which have a PEL, TLV or other recommended exposure limit. At this time, the other constituents have no known exposure limits.

Zoetis**Components****Type****Value**

Neomycin B (CAS 119-04-0)

TWA

100 µg/m3

**US. OSHA Table Z-2 (29 CFR 1910.1000)
Components****Type****Value**

Thimerosal (CAS 54-64-8)

Ceiling
TWA

0.04 mg/m3

0.01 mg/m3

**US. ACGIH Threshold Limit Values
Components****Type****Value**

Thimerosal (CAS 54-64-8)

STEL
TWA

0.03 mg/m3

0.01 mg/m3

**US. NIOSH: Pocket Guide to Chemical Hazards
Components****Type****Value**

Thimerosal (CAS 54-64-8)

STEL
TWA

0.03 mg/m3

0.01 mg/m3

Biological limit values

No biological exposure limits noted for the ingredient(s).

Exposure guidelines**US - California OELs: Skin designation**

Thimerosal (CAS 54-64-8)

Can be absorbed through the skin.

US - Tennessee OELs: Skin designation

Thimerosal (CAS 54-64-8)

Can be absorbed through the skin.

US ACGIH Threshold Limit Values: Skin designation

Thimerosal (CAS 54-64-8)

Can be absorbed through the skin.

US NIOSH Pocket Guide to Chemical Hazards: Skin designation

Thimerosal (CAS 54-64-8)

Can be absorbed through the skin.

Control banding approach

Polymyxin B: Zoetis OEB 2 - Sensitizer (control exposure to the range of 100ug/m3 to < 1000ug/m3, provide additional precautions to protect from skin contact)

Appropriate engineering controls

Good general ventilation (typically 10 air changes per hour) should be used. Ventilation rates should be matched to conditions. If applicable, use process enclosures, local exhaust ventilation, or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels to an acceptable level. General ventilation normally adequate.

Individual protection measures, such as personal protective equipment**Eye/face protection**

If contact is likely, safety glasses with side shields are recommended.

Skin protection	
Hand protection	Wear impervious gloves if skin contact is possible.
Other	Wear suitable protective clothing. Use protective clothing (uniforms, lab coats, disposable coveralls, etc.) in both production and laboratory areas.
Respiratory protection	No personal respiratory protective equipment normally required. In case of insufficient ventilation, wear suitable respiratory equipment. If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.
Thermal hazards	Not applicable.
General hygiene considerations	Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective equipment to remove contaminants.

9. Physical and chemical properties

Appearance

Physical state	Liquid.
Form	Liquid.
Color	Pink to milky red
Odor	Not available.
Odor threshold	Not available.
pH	Not available.
Melting point/freezing point	Not available.
Initial boiling point and boiling range	Not available.
Flash point	Non-flammable
Evaporation rate	Not available.
Flammability (solid, gas)	Not applicable.

Upper/lower flammability or explosive limits

Flammability limit - lower (%)	Not available.
Flammability limit - upper (%)	Not available.
Explosive limit - lower (%)	Not available.
Explosive limit - upper (%)	Not available.
Vapor pressure	Not available.
Vapor density	Not available.
Relative density	Not available.
Solubility(ies)	
Solubility (water)	Not available.
Partition coefficient (n-octanol/water)	Not available.
Auto-ignition temperature	Not available.
Decomposition temperature	Not available.
Viscosity	Not available.
Other information	
Explosive properties	Not explosive.
Oxidizing properties	Not oxidizing.

10. Stability and reactivity

Reactivity	The product is stable and non-reactive under normal conditions of use, storage and transport.
Chemical stability	Material is stable under normal conditions.
Possibility of hazardous reactions	No dangerous reaction known under conditions of normal use.

Conditions to avoid	Contact with incompatible materials. Sunlight. Store at 2-7°C. Prolonged exposure to higher temperatures may adversely affect potency. Do not freeze.
Incompatible materials	Strong oxidizing agents. This material can be denatured or inactivated by a variety of organic solvents, salts or heavy metals.
Hazardous decomposition products	No hazardous decomposition products are known.

11. Toxicological information

Information on likely routes of exposure

Inhalation	No adverse effects due to inhalation are expected.
Skin contact	Prolonged skin contact may cause temporary irritation.
Eye contact	Direct contact with eyes may cause temporary irritation.
Thimerosal	Species: Rabbit Severity: Mild

Ingestion	Expected to be a low ingestion hazard.
------------------	--

Symptoms related to the physical, chemical and toxicological characteristics	Direct contact with eyes may cause temporary irritation. Exposure may cause temporary irritation, redness, or discomfort. In the event of accidental injection, an allergic reaction may occur. Signs and symptoms might include skin rash, itching, redness or swelling. Respiratory reactions may be characterized by rhinitis, sneezing, scratchy throat, oral mucosal edema, laryngeal mucosal edema, coughing, shortness of breath, wheezing, and chest pain. Asthma like reactions occur with acute exposures in sensitized patients.
---	---

Information on toxicological effects

Acute toxicity

Components	Species	Test Results
Neomycin B (CAS 119-04-0)		
<u>Acute</u>		
Intravenous		
LD50	Mouse	24 mg/kg
Oral		
LD50	Rat	1250 mg/kg
Polymyxin B (CAS 1404-26-8)		
<u>Acute</u>		
Oral		
LD50	Mouse	790 mg/kg
Other		
LD50	Mouse	3980 ug/kg
Subcutaneous		
LD50	Rat	50 mg/kg
Thimerosal (CAS 54-64-8)		
<u>Acute</u>		
Oral		
LD50	Mouse	91 mg/kg
	Rat	75 mg/kg
Subcutaneous		
LD50	Rat	98 mg/kg
Skin corrosion/irritation	Prolonged skin contact may cause temporary irritation.	
Serious eye damage/eye irritation	Direct contact with eyes may cause temporary irritation.	
Eye Contact		
Thimerosal	Species: Rabbit Severity: Mild	

Respiratory or skin sensitization

Respiratory sensitization	Not a respiratory sensitizer.
----------------------------------	-------------------------------

Skin sensitization	This product contains merthiolate which is considered to be a skin sensitizer. This product is not expected to cause skin sensitization.
Germ cell mutagenicity	No data available to indicate product or any components present at greater than 0.1% are mutagenic or genotoxic.
Mutagenicity Polymyxin B	In Vitro Result: Negative In Vivo Result: Negative
Carcinogenicity	This product is not considered to be a carcinogen by IARC, ACGIH, NTP, or OSHA.
IARC Monographs. Overall Evaluation of Carcinogenicity	Not listed.
OSHA Specifically Regulated Substances (29 CFR 1910.1001-1050)	Not regulated.
US. National Toxicology Program (NTP) Report on Carcinogens	Not listed.
Reproductive toxicity	This product is not expected to cause reproductive or developmental effects.
Specific target organ toxicity - single exposure	Not classified.
Specific target organ toxicity - repeated exposure	Not classified.
Aspiration hazard	Not an aspiration hazard.
Chronic effects	Prolonged inhalation may be harmful.
Further information	Allergic reactions are possible. The antigens included in this product are non-infectious. All have been prepared from killed or inactivated preparations of microorganisms. This product is an oil-adjuvanted suspension. Oil-adjuvant containing products may cause severe vasospasm following accidental injection.

12. Ecological information

Ecotoxicity	The product is not classified as environmentally hazardous. However, this does not exclude the possibility that large or frequent spills can have a harmful or damaging effect on the environment. Avoid release to the environment.
Persistence and degradability	No data is available on the degradability of this product.
Bioaccumulative potential	No data available.
Mobility in soil	No data available.
Other adverse effects	No other adverse environmental effects (e.g. ozone depletion, photochemical ozone creation potential, endocrine disruption, global warming potential) are expected from this component.

13. Disposal considerations

Disposal instructions	Avoid release to the environment. Do not discharge into drains, water courses or onto the ground. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater. This product contains trace quantities of mercury and may qualify as a RCRA Hazardous Waste. Status should be confirmed using the EPA Toxicity Characteristic Leaching Procedure (TCLP). Dispose of contents/container in accordance with local/regional/national/international regulations.
Local disposal regulations	Dispose in accordance with all applicable regulations.
Hazardous waste code	The waste code should be assigned in discussion between the user, the producer and the waste disposal company. This product contains trace quantities of mercury, releases to the environment should be avoided.
Waste from residues / unused products	Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see: Disposal instructions).
Contaminated packaging	Since emptied containers may retain product residue, follow label warnings even after container is emptied.

14. Transport information

DOT

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code Not established.

15. Regulatory information

US federal regulations This product is not known to be a "Hazardous Chemical" as defined by the OSHA Hazard Communication Standard, 29 CFR 1910.1200.

TSCA Section 12(b) Export Notification (40 CFR 707, Subpt. D)

Not regulated.

CERCLA Hazardous Substance List (40 CFR 302.4)

Not listed.

SARA 304 Emergency release notification

Not regulated.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1050)

Not regulated.

Superfund Amendments and Reauthorization Act of 1986 (SARA)

Hazard categories Immediate Hazard - No
Delayed Hazard - No
Fire Hazard - No
Pressure Hazard - No
Reactivity Hazard - No

SARA 302 Extremely hazardous substance

Not listed.

SARA 311/312 Hazardous chemical No

SARA 313 (TRI reporting)
Not regulated.

Other federal regulations

Clean Air Act (CAA) Section 112 Hazardous Air Pollutants (HAPs) List

Thimerosal (CAS 54-64-8)

Clean Air Act (CAA) Section 112(r) Accidental Release Prevention (40 CFR 68.130)

Not regulated.

Safe Drinking Water Act (SDWA) Not regulated.

US state regulations WARNING: This product contains a chemical known to the State of California to cause birth defects or other reproductive harm.

US - California Proposition 65 - CRT: Listed date/Developmental toxin

Thimerosal (CAS 54-64-8)

Listed: July 1, 1990

International Inventories

Country(s) or region	Inventory name	On inventory (yes/no)*
Australia	Australian Inventory of Chemical Substances (AICS)	No
Canada	Domestic Substances List (DSL)	No
Canada	Non-Domestic Substances List (NDSL)	No
China	Inventory of Existing Chemical Substances in China (IECSC)	No
Europe	European Inventory of Existing Commercial Chemical Substances (EINECS)	No
Europe	European List of Notified Chemical Substances (ELINCS)	No
Japan	Inventory of Existing and New Chemical Substances (ENCS)	No

Country(s) or region	Inventory name	On inventory (yes/no)*
Korea	Existing Chemicals List (ECL)	No
New Zealand	New Zealand Inventory	No
Philippines	Philippine Inventory of Chemicals and Chemical Substances (PICCS)	No
United States & Puerto Rico	Toxic Substances Control Act (TSCA) Inventory	No

*A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s)
A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).

16. Other information, including date of preparation or last revision

Issue date	04-16-2017
Version #	01
Disclaimer	Zoetis Inc. believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time. The information in the sheet was written based on the best knowledge and experience currently available.
Revision information	This document has undergone significant changes and should be reviewed in its entirety.